Table 2.
Malignancy Types, Stage at Diagnosis, and Treatments for Patients Exposed or Not Exposed to TNFi
| Variable | TNFi exposed (n = 36) | TNFi naïve (n = 72) | P-value |
|---|---|---|---|
| Cancer types | |||
| Breast | 1 (3) | 2 (3) | 1.00 |
| Colon | 1 (3) | 2 (3) | 1.00 |
| Head & neck | 6 (17) | 12 (17) | 1.00 |
| Hematologic | 3 (8) | 6 (8) | 1.00 |
| Lung | 5 (14) | 10 (14) | 1.00 |
| Prostate | 10 (28) | 20 (28) | 1.00 |
| Renal | 4 (11) | 8 (11) | 1.00 |
| Skin | 5 (14) | 10 (14) | 1.00 |
| Urinary bladder | 1 (3) | 2 (3) | 1.00 |
| Age of malignancy diagnosis (yr) | 62.8 ± 8.9 | 65.4 ± 8.6 | 0.15 |
| Months of follow-up | 64.7 ± 54.8 | 62.7 ± 46.8 | 0.95 |
| Stage of cancer diagnosis | |||
| In situ | 6 (17) | 12 (17) | 1.00 |
| Stage 1 | 17 (47) | 24 (33) | 0.21 |
| Stage 2 | 5 (14) | 19 (26) | 0.22 |
| Stage 3 | 2 (5) | 6 (8) | 0.72 |
| Stage 4 | 6 (17) | 11 (15) | 1.00 |
| Cancer treatments | |||
| Chemotherapy | 4 (11) | 13 (18) | 0.41 |
| Hormonal | 2 (6) | 3 (4) | 1.00 |
| Radiation | 8 (22) | 18 (25) | 0.82 |
| Surgery | 25 (69) | 46 (64) | 0.67 |
| Months of TNFi exposure | - | ||
| Before cancer diagnosis | 32.8 ± 33.8 | 0 | |
| After cancer diagnosis | 23.1 ± 35.6 | 0 | |
| If TNFi stopped, TNFi restarted? | - | ||
| 1 Year | 11 (31) | 0 | |
| 2 Years | 1 (3) | 0 | |
| 5 Years | 0 | 0 | |
| End of study | 0 | 0 |
Values are presented as number (%) or mean±SD. Cases matched 1:2 with controls for malignancy type.
TNFi, TNF inhibitors.